Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00173-0898-03 00173-0898 dostarlimab Jemperli 50.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Apr 22, 2021 In Use
50742-0512-20 50742-0512 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sep 27, 2018 In Use
71288-0175-05 71288-0175 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Feb 1, 2025 In Use
00703-5043-03 00703-5043 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sep 1, 1995 Mar 31, 2019 No Longer Used
69097-0372-47 69097-0372 Docetaxel Anhydrous Docetaxel Anhydrous 160.0 mg/16mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug 24, 2018 Aug 26, 2020 In Use
63323-0140-10 63323-0140 Cladribine Cladribine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec 1, 2004 In Use
47781-0593-07 47781-0593 paclitaxel Paclitaxel 30.0 mg/5mL Chemotherapy Antimitotic Agent Taxane Intravenous Dec 27, 2017 Aug 1, 2020 No Longer Used
66758-0048-01 66758-0048 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov 30, 2009 May 27, 2018 In Use
00069-0700-12 00069-0700 Ondansetron hydrochloride and dextrose Ondansetron hydrochloride and dextrose 32.0 mg/50mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 1, 2009 Nov 1, 2012 In Use
55150-0355-01 55150-0355 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Apr 11, 2022 In Use
00069-0173-02 00069-0173 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jul 18, 2012 Nov 30, 2014 No Longer Used
25021-0233-20 25021-0233 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 15, 2014 In Use
67457-0618-10 67457-0618 GEMCITABINE HYDROCHLORIDE Gemcitabine 2.0 g/52.6mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec 18, 2017 In Use
70121-1755-07 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 In Use
57894-0502-05 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Oct 31, 2026 In Use
00409-0181-01 00409-0181 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug 26, 2011 In Use
55648-0186-01 55648-0186 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Mar 2, 2013 In Use
55150-0299-01 55150-0299 Fosaprepitant dimeglumine Fosaprepitant dimeglumine 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan 12, 2021 In Use
43598-0027-48 43598-0027 Melphalan Hydrochloride Melphalan Hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Apr 26, 2021 In Use
45963-0607-56 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Mar 1, 2015 In Use
63323-0733-10 63323-0733 Mesna Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Sep 5, 2001 In Use
16714-0726-01 16714-0726 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jun 15, 2017 Apr 30, 2020 In Use
00143-9384-01 00143-9384 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 8, 2020 In Use
00409-2504-10 00409-2504 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov 14, 2018 Jun 30, 2025 In Use
83077-0100-02 83077-0100 Zenocutuzumab BIZENGRI 20.0 mg/mL Immunotherapy Bispecific Antibody HER2, HER3 Intravenous Dec 4, 2024 In Use

Found 11564 results — Export these results